T. Rowe Price Associates
TNXP icon

T. Rowe Price Associates’s Tonix Pharmaceuticals TNXP Stock Holding History

T. Rowe Price Associates’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$190K Buy
13,816
+2,883
+26% +$44.4K ﹤0.01% 2861
2025
Q4 		$171K Buy
+10,933
New +$202K ﹤0.01% 2846
2022
Q2 		– Hold
0
– -$10K – 3014
2022
Q1 		– Hold
0
– – – 2964
2021
Q4 		– Hold
0
– – – 2970
2021
Q3 		– Hold
0
– – – 2934
2021
Q2 		– Hold
0
– – – 2910

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

T. Rowe Price Associates's TNXP Position: Q1 2026 in Review

T. Rowe Price Associates increased its Tonix Pharmaceuticals (TNXP) stake by 26% in Q1 2026, buying an estimated $44.4K and bringing the position to 13,816 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #2861.

T. Rowe Price Associates first reported a position in TNXP in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • T. Rowe Price Associates held 13,816 shares of Tonix Pharmaceuticals worth $190K as of Q1 2026.
  • T. Rowe Price Associates bought 2,883 Tonix Pharmaceuticals shares in Q1 2026, an estimated $44.4K.
  • Tonix Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2861 holding.
  • T. Rowe Price Associates first reported a position in Tonix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.